Cancer Vaccines: A Novel Revolutionized Approach to Cancer Therapy

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Significant advancements in tumor immunotherapy have occurred over decades.
• While infectious disease vaccines are common, few cancer vaccines are approved.
• Ideal cancer vaccines act as biological response modifiers, enhancing immunity and overcoming tumor-induced suppression.

Purpose of the Study:

• To review the landscape of cancer vaccines, including prophylactic and therapeutic types.
• To highlight approved cancer vaccines and their applications.
• To discuss challenges and recent breakthroughs in cancer vaccine development.

Main Methods:

• Review of approved prophylactic vaccines (HPV, HBV) and their targets (cervical, hepatocellular carcinoma).
• Analysis of approved therapeutic vaccines (Sipuleucel-T, BCG, T-VEC) and their indications.
• Discussion of key components like antigens and adjuvants in vaccine formulation.
• Exploration of challenges including tumor heterogeneity, antigen discovery, and delivery systems.

Main Results:

• Two prophylactic vaccines (HPV, HBV) are FDA-approved for preventing cervical and hepatocellular carcinoma.
• Three therapeutic vaccines (Sipuleucel-T, BCG, T-VEC) are approved for specific cancers like prostate, bladder, and melanoma.
• Antigens and adjuvants are crucial for optimizing immunogenicity in cancer vaccines.

Conclusions:

• Cancer vaccine development faces hurdles such as tumor heterogeneity and identifying tumor-specific antigens.
• Novel approaches like adoptive cell therapy and Chimeric Antigen Receptor T-cell therapy represent recent breakthroughs.